SG Americas Securities LLC Makes New Investment in Organogenesis Holdings Inc. (NASDAQ:ORGO)

SG Americas Securities LLC acquired a new stake in Organogenesis Holdings Inc. (NASDAQ:ORGO) during the 3rd quarter, HoldingsChannel.com reports. The fund acquired 25,086 shares of the company’s stock, valued at approximately $72,000.

Several other hedge funds have also recently bought and sold shares of ORGO. The Manufacturers Life Insurance Company increased its holdings in shares of Organogenesis by 15.4% during the second quarter. The Manufacturers Life Insurance Company now owns 30,984 shares of the company’s stock valued at $87,000 after purchasing an additional 4,130 shares during the period. Price T Rowe Associates Inc. MD increased its stake in Organogenesis by 11.8% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 50,951 shares of the company’s stock valued at $145,000 after buying an additional 5,359 shares during the period. Mackenzie Financial Corp increased its stake in Organogenesis by 46.1% during the 2nd quarter. Mackenzie Financial Corp now owns 24,328 shares of the company’s stock valued at $68,000 after buying an additional 7,678 shares during the period. Massachusetts Financial Services Co. MA lifted its stake in shares of Organogenesis by 3.5% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 269,741 shares of the company’s stock worth $755,000 after acquiring an additional 9,054 shares during the period. Finally, Pallas Capital Advisors LLC acquired a new stake in shares of Organogenesis in the 2nd quarter worth approximately $38,000. 49.57% of the stock is currently owned by institutional investors.

Organogenesis Trading Up 5.4 %

NASDAQ ORGO opened at $2.95 on Tuesday. Organogenesis Holdings Inc. has a 12 month low of $1.96 and a 12 month high of $4.70. The company’s 50 day simple moving average is $2.87 and its 200 day simple moving average is $2.77. The company has a current ratio of 2.73, a quick ratio of 2.42 and a debt-to-equity ratio of 0.22.

Organogenesis (NASDAQ:ORGO) last announced its earnings results on Thursday, August 8th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.11). Organogenesis had a negative return on equity of 6.03% and a negative net margin of 3.69%. The firm had revenue of $130.23 million for the quarter, compared to the consensus estimate of $122.48 million. On average, analysts anticipate that Organogenesis Holdings Inc. will post -0.17 EPS for the current year.

About Organogenesis

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.